1. Home
  2. BCTX vs UTSI Comparison

BCTX vs UTSI Comparison

Compare BCTX & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCTX
  • UTSI
  • Stock Information
  • Founded
  • BCTX 2014
  • UTSI 1991
  • Country
  • BCTX Canada
  • UTSI China
  • Employees
  • BCTX N/A
  • UTSI N/A
  • Industry
  • BCTX Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • BCTX Health Care
  • UTSI Telecommunications
  • Exchange
  • BCTX Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • BCTX 21.8M
  • UTSI 22.6M
  • IPO Year
  • BCTX N/A
  • UTSI 2000
  • Fundamental
  • Price
  • BCTX $12.07
  • UTSI $2.47
  • Analyst Decision
  • BCTX Strong Buy
  • UTSI
  • Analyst Count
  • BCTX 1
  • UTSI 0
  • Target Price
  • BCTX $40.00
  • UTSI N/A
  • AVG Volume (30 Days)
  • BCTX 91.9K
  • UTSI 3.9K
  • Earning Date
  • BCTX 10-16-2025
  • UTSI 08-29-2025
  • Dividend Yield
  • BCTX N/A
  • UTSI N/A
  • EPS Growth
  • BCTX N/A
  • UTSI N/A
  • EPS
  • BCTX N/A
  • UTSI N/A
  • Revenue
  • BCTX N/A
  • UTSI $9,793,000.00
  • Revenue This Year
  • BCTX N/A
  • UTSI N/A
  • Revenue Next Year
  • BCTX $380.95
  • UTSI N/A
  • P/E Ratio
  • BCTX N/A
  • UTSI N/A
  • Revenue Growth
  • BCTX N/A
  • UTSI N/A
  • 52 Week Low
  • BCTX $6.00
  • UTSI $1.84
  • 52 Week High
  • BCTX $190.50
  • UTSI $3.22
  • Technical
  • Relative Strength Index (RSI)
  • BCTX 62.20
  • UTSI 50.79
  • Support Level
  • BCTX $12.43
  • UTSI $2.43
  • Resistance Level
  • BCTX $14.68
  • UTSI $2.57
  • Average True Range (ATR)
  • BCTX 0.98
  • UTSI 0.09
  • MACD
  • BCTX -0.12
  • UTSI 0.01
  • Stochastic Oscillator
  • BCTX 68.11
  • UTSI 76.21

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: